Entering text into the input field will update the search result below

AbbVie: Buy The Humira Fear And Profit

Apr. 11, 2021 11:19 AM ETAbbVie Inc. (ABBV)50 Comments
Wealth Insights profile picture
Wealth Insights


  • AbbVie is a blue-chip pharmaceutical company that is known for its massive dividend.
  • The company will lose exclusivity on its top selling drug in a couple of years. AbbVie has begun preparing for this (see Allergan merger).
  • Despite AbbVie's strong drug portfolio, the market is pricing in the loss of Humira and keeping valuations down. This is an opportunity for long-term investors.

Photo by vzphotos/iStock Editorial via Getty Images

Pharmaceutical giant AbbVie Inc. (NYSE:ABBV) is a beloved dividend growth stock and massive player in the prescription drug space. The company's product portfolio includes Botox and Humira, the world's top selling drug. However, AbbVie's patent

This article was written by

Wealth Insights profile picture
I provide straight forward insights on stocks and markets using fundamental analysis and common sense. - Bachelor's degree in Business Administration with a concentration in Financial Analysis. Been investing and following the markets for more than a decade.- Wealth Insights is an investor, and investment author. His content is not geared to anyone's specific investment goals, time horizons, or risk tolerance. Content is for illustrative purposes only, and is not intended to displace advice from a fee based financial adviser. It is not to be taken as investment advice, or influence investor decision making. Accuracy of data is not guaranteed.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.